Drugs / XTR006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07115238 | Nov 2024 → Dec 2025 overdue | Alzheimer disease | Sinotau Pharmaceutical Group | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XTR006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07115238 ↗ |
| Modality | Diagnostic / imaging agent | “a PET radiopharmaceutical selective for NFTs” NCT07115238 ↗ |
| Route | Intravenous | “4-6 mCi IV as a bolus injection” NCT07115238 ↗ |